THE ALKALOID

Science, culture and capital — one dose at a time.

Issue #9 — May 7, 2026

THE DOSE

The Anti-Inflammatory Drug You Already Knew About

There is a quiet line of psychedelic research that has been building over the past five years and has almost nothing to do with what most people associate these compounds with. It is not about depression. It is not about ego dissolution. It is not about expanded consciousness or therapeutic breakthroughs in mental health. It is about something far less glamorous and potentially much larger in scope. Psychedelic drugs may turn out to be among the most promising new anti-inflammatory medicines developed in decades.

In an October 2025 review published in The Conversation, Nicholas Barnes, a pharmacologist at the University of Birmingham, summarized findings that are reshaping how researchers think about the therapeutic potential of these compounds. In both human cells grown in laboratory dishes and animal studies, psychedelic drugs including DMT, LSD, and a synthetic compound called R-DOI have been shown to block the release of inflammatory molecules called cytokines. Cytokines are the protein messengers that tell the immune system to attack, and they are the underlying drivers of many of the most stubborn diseases in modern medicine. Rheumatoid arthritis. Asthma. Cardiovascular disease. Major depression. Long COVID. Even brain damage following traumatic injury.

The mechanism behind the anti-inflammatory effect of psychedelics is the same receptor that produces their psychoactive effects, the 5-HT2A serotonin receptor. What was unexpected is that this receptor turns out to exist not just in the brain but throughout the body, including in immune cells, the spleen, and the lining of blood vessels. When serotonin or psychedelic compounds activate 5-HT2A receptors in immune cells, the response is dramatically anti-inflammatory. Cytokine production drops. Tissue damage from autoimmune attacks decreases. Inflammation, which has been linked to nearly every major chronic disease, falls.

The pharmacological design space this opens is enormous. R-DOI, a synthetic compound first developed in the 1990s, has been shown to produce powerful anti-inflammatory effects at doses one million times smaller than what would produce a psychedelic experience. This is a critical detail. It suggests that the therapeutic anti-inflammatory effect can be achieved without inducing any altered state of consciousness at all. The drug can be developed as a conventional anti-inflammatory medicine, prescribed and taken without any of the psychoactive baggage.

If this research holds up in clinical trials, the implications go well beyond psychiatry. Inflammation is now understood to be a central driver of most of the diseases that kill people in industrialized countries. Heart disease. Type 2 diabetes. Alzheimer's disease. Many forms of cancer. Existing anti-inflammatory drugs like NSAIDs, corticosteroids, and biologics each carry significant tradeoffs. Stomach bleeding. Immune suppression. Massive cost. Limited efficacy. A new class of anti-inflammatory drug, derived from compounds that turn out to have entirely separate therapeutic value as well, would be one of the most consequential pharmaceutical developments in modern medicine.

The strange thing about this story is that it has been hiding in plain sight. Indigenous communities have used psilocybin mushrooms, ayahuasca, and peyote for centuries, often specifically as medicines for physical illness. The Western research establishment has been studying psychedelics intensively for two decades. And yet the anti-inflammatory pathway, potentially the largest pharmaceutical opportunity in this entire space, has been the quiet undercurrent rather than the headline story.

That is now beginning to change.

QUICK HITS

• Ayahuasca reduces CRP in clinical trials. A study in patients with treatment-resistant depression found that ayahuasca administration reduced C-reactive protein, a key inflammation marker, 48 hours after dosing. The size of the CRP drop correlated with the size of mood improvement. The implication is striking: some of the antidepressant effect of psychedelics may be working through reduced inflammation, not just neurochemistry.
• R-DOI works at almost zero dose. The synthetic psychedelic R-DOI produces full anti-inflammatory effects at doses approximately one million times smaller than what would produce psychoactive effects. This is the foundation for designing non-hallucinogenic psychedelic-derived drugs for inflammatory conditions.
• The 5-HT2A receptor lives outside the brain. Receptors for psychedelics were once thought to exist primarily in the cerebral cortex. Research now shows they are present in immune cells, vascular endothelium, gut tissue, and the spleen. Activating these receptors with psychedelic compounds appears to consistently reduce inflammatory cytokine release.
• TBI may be a target. Animal research suggests psychedelic compounds reduce neuroinflammation following traumatic brain injury. With the Department of Veterans Affairs already running multiple psychedelic clinical trials for PTSD in veterans, the inflammation pathway adds another rationale for that population.
• Compass Pathways' COMP360 has anti-inflammatory data. Beyond the depression efficacy that earned the priority review voucher, preclinical data on psilocybin formulations consistently show cytokine reduction. The full implications of this for FDA labeling and post-approval indication expansion are not yet clear, but they are substantial.

SCIENCE DESK

What inflammation actually is

Inflammation is one of those words that gets used so commonly in popular health discourse that its actual meaning can blur. In medical terms, inflammation is the immune system's response to perceived threat. When the body encounters injury, infection, or chemical irritation, immune cells release cytokines to coordinate the defensive response. Blood flow increases. White blood cells migrate to the affected site. Tissue swells. The classic signs are redness, heat, swelling, pain, and loss of function.

Acute inflammation is essential and useful. It is how the body fights infection and heals wounds. The problem is chronic inflammation. When the immune system stays activated for months or years without an active threat, the same machinery that heals begins to harm. The cytokines that normally kill invading microbes start damaging healthy tissue. Joint cartilage erodes in rheumatoid arthritis. Blood vessel walls accumulate plaque in atherosclerosis. Brain cells die in chronic neuroinflammation. Insulin resistance develops in metabolic disease.

The big shift in medical thinking over the past two decades is the recognition that chronic inflammation is not just a symptom of disease. It is, in many cases, the underlying mechanism. Heart disease, depression, diabetes, dementia, cancer, autoimmune conditions, and chronic pain all share inflammation as a common substrate. This is why anti-inflammatory drugs are so heavily prescribed and why limitations of existing options matter so much.

What psychedelic compounds appear to be doing at the 5-HT2A receptor in immune cells is exactly what the most expensive biologic drugs are designed to do. They reduce the release of pro-inflammatory cytokines. The difference is mechanism, cost, and side effect profile. Biologics like adalimumab cost tens of thousands of dollars per year and require injection. They suppress the immune system broadly, increasing infection risk. Psychedelic-derived anti-inflammatories, particularly non-hallucinogenic variants like R-DOI and engineered analogs, may achieve similar results with oral dosing, lower cost, and a different side effect profile. Whether they can match the potency of existing biologics in late-stage disease remains an open question. The research is genuinely promising and genuinely early.

MARKET WATCH

The anti-inflammatory pathway represents a strategic expansion of the addressable market for psychedelic biotech that most current valuations have not yet incorporated. Compass Pathways and Cybin are valued primarily on their psychiatric pipelines, with depression, PTSD, and addiction as the lead indications. The total annual market for these conditions, while substantial, is dwarfed by the inflammatory disease market. Rheumatoid arthritis treatment alone represents over $30 billion in annual spending. Add cardiovascular disease, autoimmune conditions, and chronic neuroinflammation, and the addressable market for new anti-inflammatory drugs runs into hundreds of billions of dollars globally.

Companies positioned for this opportunity include those developing non-hallucinogenic 5-HT2A agonists. Delix Therapeutics is one of the most prominent, focused on engineered compounds that retain therapeutic effects without psychedelic experience. Mindset Pharma, Awakn Life Sciences, and several private companies are also working in this design space. Whether any of these compounds reach late-stage trials specifically for inflammatory indications, rather than as analogs of psychiatric psychedelics, will be a question worth tracking closely.

Worth noting that the regulatory pathway for non-hallucinogenic anti-inflammatory drugs derived from psychedelic chemistry would likely not require Schedule I scheduling. This is a significant advantage. Drugs that don't produce psychoactive effects don't require the complex DEA scheduling, FDA REMS programs, or clinic-based administration that surrounds compounds like psilocybin in clinical use. They can be developed and prescribed like any conventional medication.

The cannabis sector continues its regulatory limbo. Federal rescheduling remains slow-walked. The November hemp THC deadline approaches without legislative resolution. Capital flows into psychedelic biotech remain healthy following the executive order, with Compass Pathways' priority voucher and AtaiBeckley's clinical pipeline drawing the most institutional attention. The anti-inflammatory expansion of the psychedelic thesis is not yet priced into the sector but may become a major story over the next 18 to 24 months.

THE LAST WORD

There is a quiet pattern worth noticing across nearly everything The Alkaloid has covered in its first nine issues. Compounds that indigenous traditions have used for centuries to address physical and spiritual suffering keep turning out, when investigated through Western pharmaceutical methods, to have therapeutic mechanisms that map onto the conditions they were traditionally used to treat. Ayahuasca was used by Amazonian healers for inflammatory conditions and post-illness recovery. Modern research now shows it reduces inflammatory cytokines. Psilocybin mushrooms were used for grief, melancholy, and what we would now call depression. Modern research now shows they alter neural circuits implicated in those conditions. Iboga was used in West African healing traditions for addiction. Modern research now shows ibogaine interrupts addiction cycles in ways no other compound has matched.

The pattern is so consistent it is almost embarrassing for the Western scientific establishment to keep encountering it as if it were new. The traditional medicine systems that developed these uses over generations were not making things up. They were observing what the compounds actually did. The chemistry, the receptor pharmacology, the cytokine pathways, all of that is the explanatory infrastructure that science has finally built around what people noticed and remembered and passed on for centuries.

The anti-inflammatory pathway may be the most consequential example yet. If R-DOI and its analogs can be developed into oral medications for chronic inflammatory disease, the impact on global health could rival the development of statins or antibiotics. The drugs that produce that impact will almost certainly be patented, priced, and distributed by pharmaceutical companies with no acknowledgment of the indigenous healers who first observed what these molecules could do. That is how this kind of value capture has always worked.

The science, when it eventually arrives, will tell the same story the traditions told. The infrastructure of acknowledgment, equity, and benefit-sharing for the communities that preserved this knowledge through prohibition will need to be built deliberately. It will not happen by default.

— The Alkaloid

Sources

1. The Conversation — From trips to treatments: how psychedelics could revolutionise anti-inflammatory medicine: https://theconversation.com/from-trips-to-treatments-how-psychedelics-could-revolutionise-anti-inflammatory-medicine-264610
2. The Medicine Maker — Can Psychedelics Influence the Immune System?: https://themedicinemaker.com/issues/2025/articles/sept/can-psychedelics-influence-the-immune-system/
3. Marijuana Moment — Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment': https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-suggests/
4. ScienceDirect — Psychedelics in neuroinflammation: Mechanisms and therapeutic potential: https://www.sciencedirect.com/science/article/abs/pii/S0278584625000326
5. ACS Chemical Neuroscience — Classic Psychedelics in Pain Modulation: https://pubs.acs.org/doi/10.1021/acschemneuro.5c00152
6. PubMed — Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights: https://pubmed.ncbi.nlm.nih.gov/38401463/
7. medRxiv — Psilocybin induces acute and persisting alterations in immune status and the stress response: https://www.medrxiv.org/content/10.1101/2022.10.31.22281688.full.pdf
8. Massive Science — Scientists identify a powerful anti-inflammatory compound in psychedelic drugs: https://massivesci.com/notes/psychedelic-drugs-serotonin-psilocybin-dmt/

The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: thealkaloid.ghost.io